Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$51.08 USD

51.08
23,330,915

+2.32 (4.76%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $51.18 +0.10 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (68 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks News

Zacks Equity Research

Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus

Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.

Zacks Equity Research

Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates

Novo Nordisk (NVO) reports better-than-expected results for Q1. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

Zacks Equity Research

The Zacks Analyst Blog Highlights Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen

Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen have been included in this Analyst Blog.

Indrajit Bandyopadhyay headshot

5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates

Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.

Zacks Equity Research

The Zacks Analyst Blog Highlights Novo Nordisk, Advanced Micro Devices, Netflix, Merck, and Marsh & McLennan

Novo Nordisk, Advanced Micro Devices, Netflix, Merck, and Marsh & McLennan have been included in this Analyst Blog.

Mark Vickery headshot

Top Research Reports for Novo Nordisk, AMD & Netflix

Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Advanced Micro Devices, Inc. (AMD), and Netflix, Inc. (NFLX).

Zacks Equity Research

4 Reasons to Add Novo Nordisk (NVO) Stock to Your Portfolio

Novo Nordisk's (NVO) portfolio of marketed drugs are driving year over year growth. The company has one of the broadest diabetes portfolios in the industry.

Zacks Equity Research

The Zacks Analyst Blog Highlights Apple, The Procter & Gamble, Chevron, Novo Nordisk and Canadian Natural Resources Limited

Apple, The Procter & Gamble, Chevron, Novo Nordisk and Canadian Natural Resources Limited have been included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Apple, P & G, Chevron & Others

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), The Procter & Gamble Company (PG), and Chevron Corporation (CVX).

Zacks Equity Research

Novo Nordisk (NVO) Gets FDA Nod for Ozempic's Label Expansion

The FDA approves Novo Nordisk's (NVO) Ozempic 2.0 mg dose for the treatment of adults with type II diabetes. The medicine is now approved at 0.5 mg, 1.0 mg and 2.0 mg doses for the given indication.

Zacks Equity Research

BAYRY vs. NVO: Which Stock Is the Better Value Option?

BAYRY vs. NVO: Which Stock Is the Better Value Option?

Zacks Equity Research

The Zacks Analyst Blog Highlights: The Procter & Gamble Co., Chevron Corp., Novo Nordisk A/S, FedEx Corp. and Palo Alto Networks, Inc

The Procter & Gamble Co., Chevron Corp., Novo Nordisk A/S, FedEx Corp. and Palo Alto Networks, Inc are highlighted in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Procter & Gamble, Chevron & Novo Nordisk

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Chevron Corporation (CVX), and Novo Nordisk A/S (NVO).

Zacks Equity Research

Prothena (PRTA) Q4 Earnings Beat, Pipeline Progress in Focus

Prothena beats on earnings and revenues in the fourth quarter of 2021. The company's progress with its AD pipeline is encouraging.

Zacks Equity Research

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

Zacks Equity Research

Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates

Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

Indrajit Bandyopadhyay headshot

Pharma Stocks to Report Q4 Earnings on Feb 2: ABBV, NVS & NVO

Let us take a look at three large pharma companies - ABBV, NVS and NVO - due to release their quarterly results on Feb 2.

Zacks Equity Research

GSK vs. NVO: Which Stock Is the Better Value Option?

GSK vs. NVO: Which Stock Is the Better Value Option?

Zacks Equity Research

Lilly (LLY) Inks Metabolic Disorders Therapy Development Deal

Lilly (LLY) inks a strategic collaboration with Regor Therapeutics to discover and develop novel therapies for metabolic disorders.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Netflix, Salesforce, Novo Nordisk, Caterpillar and ConocoPhillips

The Zacks Analyst Blog Highlights: Netflix, Salesforce, Novo Nordisk, Caterpillar and ConocoPhillips

Mark Vickery headshot

Top Research Reports for Netflix, salesforce & Novo Nordisk

Today's Research Daily features new research reports on 16 major stocks, including Netflix, Inc. (NFLX), salesforce.com, inc. (CRM), and Novo Nordisk (NVO).

Zacks Equity Research

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

Zacks Equity Research

GSK vs. NVO: Which Stock Should Value Investors Buy Now?

GSK vs. NVO: Which Stock Is the Better Value Option?

Zacks Equity Research

Novo Nordisk (NVO) Set to Acquire Dicerna for $3.3 Billion

Novo Nordisk (NVO) inks agreement to acquire Dicerna for $3.3 billion. The company is looking to boost its RNAi research platform with this acquisition.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk

The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk